Perforation of peptic ulcer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) Age 18-80 years old gender is not limited; 2) Clearly diagnosed with peptic ulcer perforation (in accordance with the criteria of Guidelines for the Diagnosis and Treatment of Peptic Ulcer (2021 edition) and Expert Consensus on the Surgical Treatment of Peptic Ulcer Perforation (2023 edition) and the basis for confirming the diagnosis includes clinical symptoms signs imaging examinations and surgical findings); (3) Undergo laparoscopic ulcer perforation repair with successful completion of the operation without serious complications; (4) Diagnosed with postoperative gastrointestinal dysfunction within 48 hours according to the Rome IV criteria (failure to pass gas for 24 hours after surgery or the presence of at least two of the following symptoms: recurrent nausea vomiting abdominal distension and diminished or absent bowel sounds); 5) Enrollment within 72 hours after surgery; 6) The patients were in a clear state of mind able to understand and cooperate with the study and voluntarily signed an informed consent form; 7) The expected length of hospitalization is = 7 days and able to complete all study procedures.
Exclusion criteria
Exclusion criteria: 1) Perforation diameter >2 cm or surgical finding of severe peritoneal contamination (peritoneal fluid >1000 ml or diffuse fecal peritonitis); 2) Intraoperative perforation found to be due to other causes (e.g. malignant tumor inflammatory bowel disease or trauma); 3) concurrent intraoperative vagotomy pyloroplasty or other procedures affecting gastrointestinal motility; (4) A clear history of chronic gastrointestinal dyskinesia (e.g. functional dyspepsia irritable bowel syndrome etc.); 5) have undergone abdominal or pelvic surgery within the last 6 months; (6) Severe cardiac hepatic or renal insufficiency (American Society of Anesthesiologists ASA classification > grade III); 7) There are contraindications to acupuncture: a) Bleeding disorders or coagulation disorders (INR>1.5 or platelets<50×10^9/L); b) Skin infections or serious skin diseases that interfere with acupoint therapy; c) Electronic implanted devices such as pacemakers; 8) Pregnant or lactating women; 9) Patients with mental illness or cognitive dysfunction who are unable to cooperate with assessment and treatment; 10) Participants who have participated in other clinical trials within 4 weeks prior to screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The time of the first exhaust and defecation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life indicators;The time for the first tolerance to liquid and semi-liquid foods;Postoperative hospital stay; | — |
Countries
China
Contacts
The Affiliated Hospital of Guizhou Medical University